UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Progress of ATM inhibitors: Opportunities and challenges

European journal of medicinal chemistry, 2024-11, Vol.277, p.116781, Article 116781

2024

Volltextzugriff (PDF)

Emerging pharmacological approaches for Huntington's disease

European journal of pharmacology, 2024-10, Vol.980, p.176873, Article 176873

2024

Volltextzugriff (PDF)

Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington's disease

Expert review of neurotherapeutics, 2024-10, Vol.24 (10), p.937-940

2024

Volltextzugriff (PDF)

Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders

Psychopharmacology, 2024-10, Vol.241 (10), p.1939-1954

2024

Volltextzugriff (PDF)

Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting

Molecular medicine (Cambridge, Mass.), 2024-09, Vol.30 (1), p.158-21, Article 158

2024

Volltextzugriff (PDF)

Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease

Proceedings of the National Academy of Sciences - PNAS, 2024-09, Vol.121 (39), p.e2406308121

2024

Volltextzugriff (PDF)

Evaluating AlphaFold for Clinical Pharmacology and Pharmacogenetics: A Case-Study of Huntingtin Variants Linked to Huntington’s Disease

The AAPS journal, 2024-09, Vol.26 (6), p.106, Article 106

2024

Volltextzugriff (PDF)

A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways

Chemistry : a European journal, 2024-09, Vol.30 (52), p.e202400080-n/a

2024

Volltextzugriff (PDF)

The known and unknown of post-pump chorea: a case report on robust steroid responsiveness implicating occult neuroinflammation

Frontiers in immunology, 2024-09, Vol.15, p.1458022

2024

Volltextzugriff (PDF)

Efficacy and safety of riluzole for treating motor function in rare dyskinesia syndromes: a systematic review with meta-analysis

Journal of international medical research, 2024-09, Vol.52 (9), p.3000605241276489

2024

Volltextzugriff (PDF)

Epigenetic Orchestration of Neurodegenerative Disorders: A Possible Target for Curcumin as a Therapeutic

Neurochemical research, 2024-09, Vol.49 (9), p.2319-2335

2024

Volltextzugriff (PDF)

Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model

CNS neuroscience & therapeutics, 2024-09, Vol.30 (9), p.e70025-n/a

2024

Volltextzugriff (PDF)

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

BMJ open, 2024-08, Vol.14 (8), p.e087983

2024

Volltextzugriff (PDF)

Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach

Journal of cellular and molecular medicine, 2024-08, Vol.28 (16), p.e18588-n/a

2024

Volltextzugriff (PDF)

Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects

Neurochemical research, 2024-08, Vol.49 (8), p.1926-1944

2024

Volltextzugriff (PDF)

Mitochondrial targeted antioxidants as potential therapy for huntington’s disease

Pharmacological reports, 2024-08, Vol.76 (4), p.693-713

2024

Volltextzugriff (PDF)

Neuroprotective effects of levothyroxine on cognition deficits and memory in an experimental model of Huntingtonʼs disease in rats: An electrophysiological study

Naunyn-Schmiedeberg's archives of pharmacology, 2024-08, Vol.397 (8), p.5939-5951

2024

Volltextzugriff (PDF)

Huntington’s Disease: Latest Frontiers in Therapeutics

Current neurology and neuroscience reports, 2024-08, Vol.24 (8), p.255-264

2024

Volltextzugriff (PDF)

Effect of Capsaicin on 3-NP-Induced Neurotoxicity: A Pre-Clinical Study

Neurochemical research, 2024-08, Vol.49 (8), p.2038-2059

2024

Volltextzugriff (PDF)

6-shogaol against 3-Nitropropionic acid-induced Huntington's disease in rodents: Based on molecular docking/targeting pro-inflammatory cytokines/NF-κB-BDNF-Nrf2 pathway

PloS one, 2024-07, Vol.19 (7), p.e0305358

2024

Volltextzugriff (PDF)

Gastrodin Improves the Activity of the Ubiquitin-Proteasome System and the Autophagy-Lysosome Pathway to Degrade Mutant Huntingtin

International journal of molecular sciences, 2024-07, Vol.25 (14), p.7709

2024

Volltextzugriff (PDF)

Brain cholesterol therapy for Huntington's disease – Does it make sense?

Clinical and translational medicine, 2024-07, Vol.14 (7), p.e1746-n/a

2024

Volltextzugriff (PDF)

Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease

Clinical and translational science, 2024-07, Vol.17 (7), p.e13852-n/a

2024

Volltextzugriff (PDF)

Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases

Medicinal research reviews, 2024-07, Vol.44 (4), p.1404-1445

2024

Volltextzugriff (PDF)

New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders

Synapse (New York, N.Y.), 2024-07, Vol.78 (4), p.e22301-n/a

2024

Volltextzugriff (PDF)

1 – 25 von 2.410

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.157)
Mit Volltextzugriff
(1.658)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.991)
Life Sciences & Biomedicine
(1.877)
Humans
(1.863)
Huntington Disease - Drug Therapy
(1.482)
Animals
(1.129)
Neurosciences & Neurology
(943)
Huntington's Disease
(855)
Male
(826)
Neurosciences
(670)
Female
(657)
Disease Models, Animal
(513)
Huntingtons Disease
(500)
Middle Aged
(470)
Pharmacology & Pharmacy
(461)
Huntington Disease - Metabolism
(447)
Neurology
(447)
Clinical Neurology
(444)
Adult
(439)
Mice
(433)
Huntington Disease - Genetics
(408)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Progress of ATM inhibitors: Opportunities and challenges

Emerging pharmacological approaches for Huntington's disease

Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington's disease

Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders

Parthenolide ameliorates 3-nitropropionic acid-induced Huntington's disease-like aberrations via modulating NLRP3 inflammasome, reducing microglial activation and inducing astrocyte shifting

Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease

Evaluating AlphaFold for Clinical Pharmacology and Pharmacogenetics: A Case-Study of Huntingtin Variants Linked to Huntington’s Disease

A Peptide Strategy for Inhibiting Different Protein Aggregation Pathways

The known and unknown of post-pump chorea: a case report on robust steroid responsiveness implicating occult neuroinflammation

Efficacy and safety of riluzole for treating motor function in rare dyskinesia syndromes: a systematic review with meta-analysis

Epigenetic Orchestration of Neurodegenerative Disorders: A Possible Target for Curcumin as a Therapeutic

Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington’s disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach

Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects

Mitochondrial targeted antioxidants as potential therapy for huntington’s disease

Neuroprotective effects of levothyroxine on cognition deficits and memory in an experimental model of Huntingtonʼs disease in rats: An electrophysiological study

Huntington’s Disease: Latest Frontiers in Therapeutics

Effect of Capsaicin on 3-NP-Induced Neurotoxicity: A Pre-Clinical Study

6-shogaol against 3-Nitropropionic acid-induced Huntington's disease in rodents: Based on molecular docking/targeting pro-inflammatory cytokines/NF-κB-BDNF-Nrf2 pathway

Gastrodin Improves the Activity of the Ubiquitin-Proteasome System and the Autophagy-Lysosome Pathway to Degrade Mutant Huntingtin

Brain cholesterol therapy for Huntington's disease – Does it make sense?

Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease

Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases

New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders

Suchergebnisse filtern